Redmile director nominee awarded 87,900 Fate Therapeutics (FATE) stock options

Rhea-AI Filing Summary

Fate Therapeutics reported that an entity associated with Redmile Group received a new stock option award linked to board service. The option covers 87,900 shares of common stock at an exercise price of $2.06 per share and expires on June 12, 2036. It was granted to director Michael Lee for his role on the board, but, under Redmile’s policies, he holds it as a nominee for the sole benefit of Redmile, which has the economic and voting rights. The option will vest in full on the earlier of June 12, 2027 or the date of the company’s 2027 annual stockholder meeting, subject to Lee’s continued board service. Redmile and principal Jeremy Green disclaim beneficial ownership except to any pecuniary interest they may have.

Insights

Equity Compensation & Governance Analyst

Routine board compensation grant via Redmile-linked director.

This Form 4 shows a standard equity compensation grant rather than an open-market trade. A Redmile-associated director received options for 87,900 shares of Fate Therapeutics common stock at an exercise price of $2.06 per share, expiring on June 12, 2036.

The award vests in a single tranche on the earlier of June 12, 2027 or the 2027 annual stockholder meeting, contingent on continued board service. Footnotes clarify that Michael Lee holds the award as a nominee for Redmile, which has the economic and voting rights, while Redmile and Jeremy Green formally disclaim beneficial ownership beyond any pecuniary interest.

Because this is a compensation-related option grant with no share sales, it is generally viewed as routine. It does, however, underline Redmile’s continued board-level involvement through a director elected as its representative and characterized as a director by deputization under Section 16.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Redmile Group, LLC, Green Jeremy

Role null | null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	87,900	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 87,900 shares (Indirect, See Footnotes)

Footnotes (1)

1. The stock option will vest in full and become exercisable upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to Michael Lee's continued service on the board of directors of the Issuer through the applicable vesting date. The stock option award was granted to Mr. Lee, a managing director of Redmile Group, LLC ("Redmile"), in connection with his service as a member of the board of directors of the Issuer. Pursuant to the policies of Redmile, Mr. Lee holds this equity award as a nominee on behalf, and for the sole benefit, of Redmile and has assigned all economic, pecuniary and voting rights in respect of the equity award to Redmile. Mr. Lee disclaims beneficial ownership of the equity award, and the filing of this Form 4 shall not be deemed an admission that Mr. Lee is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. The stock option award may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the equity award except to the extent of their pecuniary interest therein, if any, and this Form 4 shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Mr. Lee, a member of the board of directors of the Issuer and a managing director of Redmile, was elected to the board of the Issuer as a representative of Redmile and its affiliates. As a result, the Reporting Persons are directors by deputization for purposes of Section 16 of the Securities Exchange Act of 1934, as amended.

Key Figures

Option grant size: 87,900 shares Exercise price: $2.06 per share Expiration date: June 12, 2036 +3 more

6 metrics

Option grant size 87,900 shares Stock Option (Right to Buy) underlying common stock

Exercise price $2.06 per share Conversion or exercise price of stock option

Expiration date June 12, 2036 Option expiration for the stock option award

Vesting date trigger June 12, 2027 Earlier of this date or 2027 annual meeting, subject to service

Transaction code A (Grant, award, or other acquisition) Indicates derivative acquisition, not market purchase or sale

Shares after transaction 87,900 derivative shares Total stock option derivative shares following transaction

Key Terms

Stock Option (Right to Buy), beneficial ownership, pecuniary interest, directors by deputization, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

beneficial ownership regulatory

"Mr. Lee disclaims beneficial ownership of the equity award"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

pecuniary interest financial

"disclaim beneficial ownership of the equity award except to the extent of their pecuniary interest therein"

directors by deputization regulatory

"the Reporting Persons are directors by deputization for purposes of Section 16"

Section 16 of the Securities Exchange Act of 1934 regulatory

"for purposes of Section 16 of the Securities Exchange Act of 1934, as amended"

A provision of federal securities law that requires company insiders—directors, officers and large shareholders—to publicly report their stock holdings and trades and to surrender any “short-swing” profits from purchases and sales within a six-month window. It acts like a rule that forces leaders to announce their trades and prevents quick buy-sell windfalls, giving investors transparency into insider activity and reducing opportunities for unfair gain.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Redmile Group, LLC

(Last) (First) (Middle)

900 LARKSPUR LANDING CIRCLE,

SUITE 270

(Street)

LARKSPUR CALIFORNIA 94939

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
FATE THERAPEUTICS INC [ FATE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.06	06/12/2026		A		87,900		(1)	06/12/2036	Common Stock	87,900	$0.00	87,900	I	See Footnotes(2)(3)(4)

1. Name and Address of Reporting Person^*

Redmile Group, LLC

(Last) (First) (Middle)

900 LARKSPUR LANDING CIRCLE,

SUITE 270

(Street)

LARKSPUR CALIFORNIA 94939

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Green Jeremy

(Last) (First) (Middle)

C/O REDMILE GROUP, LLC (NY OFFICE)

45 W. 27TH STREET, FLOOR 11

(Street)

NEW YORK NEW YORK 10001

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

Explanation of Responses:

1. The stock option will vest in full and become exercisable upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to Michael Lee's continued service on the board of directors of the Issuer through the applicable vesting date.

2. The stock option award was granted to Mr. Lee, a managing director of Redmile Group, LLC ("Redmile"), in connection with his service as a member of the board of directors of the Issuer. Pursuant to the policies of Redmile, Mr. Lee holds this equity award as a nominee on behalf, and for the sole benefit, of Redmile and has assigned all economic, pecuniary and voting rights in respect of the equity award to Redmile. Mr. Lee disclaims beneficial ownership of the equity award, and the filing of this Form 4 shall not be deemed an admission that Mr. Lee is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

3. The stock option award may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the equity award except to the extent of their pecuniary interest therein, if any, and this Form 4 shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

4. Mr. Lee, a member of the board of directors of the Issuer and a managing director of Redmile, was elected to the board of the Issuer as a representative of Redmile and its affiliates. As a result, the Reporting Persons are directors by deputization for purposes of Section 16 of the Securities Exchange Act of 1934, as amended.

	By: /s/ Jeremy Green, Managing Member of Redmile Group, LLC	06/15/2026
	/s/ Jeremy Green	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Fate Therapeutics (FATE) report in this Form 4?

Fate Therapeutics reported a grant of stock options covering 87,900 shares of common stock as board compensation. The options were awarded to director Michael Lee and are held for the sole benefit of Redmile Group under its internal policies and governance structure.

What are the key terms of the Redmile-related stock option grant at Fate Therapeutics (FATE)?

The stock option covers 87,900 shares of Fate Therapeutics common stock with an exercise price of $2.06 per share. It expires June 12, 2036 and will vest in full on the earlier of June 12, 2027 or the company’s 2027 annual stockholder meeting.

Who actually benefits from the new Fate Therapeutics (FATE) stock option grant?

The option was granted to director Michael Lee but is held as a nominee for the sole benefit of Redmile Group. Redmile has the economic, pecuniary and voting rights, while Lee disclaims beneficial ownership under Section 16 except as described in the footnotes.

Is the Fate Therapeutics (FATE) Form 4 transaction a stock purchase or sale?

No open-market purchase or sale occurred in this Form 4. It reflects a compensation-related stock option grant, categorized as an acquisition of derivative securities, rather than a buy or sell of existing Fate Therapeutics common shares on the market.

How and when do the Fate Therapeutics (FATE) options granted to the Redmile representative vest?

The stock options will vest in full and become exercisable on the earlier of June 12, 2027 or the date of Fate Therapeutics’ 2027 annual stockholder meeting, provided Michael Lee continues serving on the company’s board of directors through the applicable vesting date.

How is Jeremy Green related to the Redmile-held Fate Therapeutics (FATE) options?

The option award may be deemed beneficially owned by Jeremy Green as principal of Redmile. Both Redmile and Green disclaim beneficial ownership of the equity award except to the extent of any pecuniary interest they may have, as outlined in the Form 4 footnotes.